Education
About Us
Working with TipRanks
Follow Us
Kobayashi Pharmaceutical Co Ltd (JP:4967)
:4967
RESEARCH TOOLSreports
Top Page
Kobayashi Pharmaceutical Co
(OTC:4967)
56Neutral
Kobayashi Pharmaceutical Co (4967) vs. S&P 500 (SPY)
Market Cap
$397.37B
Dividend Yield1.79%
Average Volume (3M)251.48K
Price to Earnings (P/E)39.6
Beta (1Y)0.32
Revenue Growth-4.53%
EPS Growth-49.49%
CountryJP
Employees3,615
SectorHealthcare
Sector Strength56
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)135.42
Shares Outstanding78,050,000
10 Day Avg. Volume151,790
30 Day Avg. Volume251,480
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,349.78Price Target Upside-0.15% Downside
Rating ConsensusHold
Number of Analyst Covering2
Kobayashi Pharmaceutical Co Business Overview & Revenue Model
Company DescriptionKobayashi Pharmaceutical Co., Ltd. (TSE: 4967) is a leading Japanese company specializing in the development, manufacturing, and marketing of consumer healthcare products, pharmaceuticals, and medical devices. Established in 1919, the company operates in several sectors including over-the-counter (OTC) health products, household products, and medical devices. Kobayashi Pharmaceutical is renowned for its innovative approach to product development, with a diverse portfolio that includes pain relief products, gastrointestinal medications, sanitary products, and home care solutions.
How the Company Makes MoneyKobayashi Pharmaceutical Co. generates revenue through the sale of its diverse range of products across multiple categories. The company's primary revenue streams are derived from its healthcare and household product segments. In the healthcare segment, Kobayashi offers OTC medications, supplements, and medical devices, which provide consistent revenue from consumer purchases. The household products segment includes a variety of personal care and home maintenance products, which contribute significantly to the company's total earnings. Additionally, the company benefits from strategic partnerships and distribution agreements that expand its market reach both domestically and internationally. Kobayashi Pharmaceutical leverages its strong brand reputation and continuous innovation to maintain a competitive edge and ensure steady revenue growth.
Kobayashi Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 165.60B | 173.46B | 166.26B | 155.25B | 150.51B | Gross Profit |
| 87.60B | 96.38B | 92.33B | 88.77B | 85.27B | EBIT |
| 24.86B | 25.78B | 26.67B | 26.07B | 25.94B | EBITDA |
| 32.73B | 33.65B | 31.86B | 30.79B | 29.91B | Net Income Common Stockholders |
| 10.07B | 20.34B | 20.02B | 19.71B | 19.20B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 65.75B | 79.84B | 104.53B | 109.05B | 94.34B | Total Assets |
| 265.37B | 267.47B | 255.83B | 252.55B | 238.37B | Total Debt |
| 846.00M | 987.00M | 792.00M | 630.00M | 688.00M | Net Debt |
| -50.03B | -70.55B | -95.44B | -94.39B | -77.56B | Total Liabilities |
| 51.90B | 62.66B | 57.93B | 56.95B | 55.78B | Stockholders Equity |
| 213.47B | 204.82B | 197.90B | 195.60B | 182.58B |
| Cash Flow | Free Cash Flow | |||
| -14.81B | 4.79B | 15.69B | 18.23B | 19.84B | Operating Cash Flow |
| 11.25B | 18.36B | 31.91B | 22.42B | 23.99B | Investing Cash Flow |
| -18.41B | -19.58B | -14.31B | 7.99B | -12.66B | Financing Cash Flow |
| -7.77B | -19.46B | -20.76B | -10.38B | -6.02B |
Kobayashi Pharmaceutical Co Technical Analysis
Negative
5358.00
Price Trends
5553.88
Negative
5705.60
Negative
5633.20
Negative
Market Momentum
-45.53
Positive
41.81
Neutral
17.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Negative. The current price of 5358 is below the 20-day moving average (MA) of 5403.60, below the 50-day MA of 5553.88, and below the 200-day MA of 5633.20, indicating a bearish trend. The MACD of -45.53 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 17.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4967.
Kobayashi Pharmaceutical Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $63.07B | 27.83 | 3.26% | 2.75% | 5.21% | 33.10% | |
75 Outperform | ¥782.90B | 10.59 | 9.06% | 4.16% | -2.16% | -40.39% | |
65 Neutral | ¥1.20T | 20.65 | 6.83% | 3.58% | 5.63% | 30.61% | |
60 Neutral | ¥31.36B | 17.21 | 2.93% | 4.86% | 4.05% | ||
56 Neutral | $397.37B | 39.57 | 4.75% | 1.79% | -4.53% | -49.49% | |
55 Neutral | ¥932.20B | 496.62 | 1.71% | 1.80% | -149.74% | ||
52 Neutral | $5.35B | 3.81 | -42.57% | 2.86% | 17.10% | 1.33% |
* Healthcare Sector Average
Performance Comparison
JP:4967
Kobayashi Pharmaceutical Co
5,358.00
99.36
1.89%
JP:4911
Shiseido Company,Limited
2,333.50
-1,912.45
-45.04%
JP:4951
S.T.Corporation
1,503.00
13.88
0.93%
JP:4528
ONO Pharmaceutical Co
1,667.00
-530.64
-24.15%
JP:4917
Mandom
1,402.00
106.68
8.24%
JP:4523
Eisai Co
4,271.00
-2,110.05
-33.07%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.